Global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Insights, Forecast to 2028
Market Analysis and Insights: Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market
This report focuses on global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies market.
In 2021, the global T-Cell & NK-Cell Engaging Bispecific Antibodies market size was US$ 472 million and it is expected to reach US$ 5072 million by the end of 2028, with a CAGR of 40.82% during 2021-2028. In Japan the T-Cell & NK-Cell Engaging Bispecific Antibodies market size is expected to grow from US$ 1.88 million in 2021 to US$ 173.15 million by 2028, at a CAGR of 99.82% during the forecast period.
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Scope and Market Size
T-Cell & NK-Cell Engaging Bispecific Antibodies market is segmented by players, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global T-Cell & NK-Cell Engaging Bispecific Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and By Application in terms of revenue and forecast for the period 2017-2028.
By Company
Amgen
Immunocore
Johnson & Johnson
Roche
Company Five
AbbVie
MacroGenics
Regeneron
Astellas Pharma
GEMoaB Monoclonals
Molecular Partners
AstraZeneca
Merck
Eli Lilly
IGM Biosciences
Novartis
CytomX Therapeutics
Lava Therapeutics
Takeda
Segment by Type
T Cell Engagers
NK Cell Engagers
Segment by Application
Hematological Cancers
Solid Tumors
By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
Southeast Asia
Australia
India
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
South America
Brazil
Rest of South America
Middle East & Africa
Middle East
Africa
- 1 REPORT OVERVIEW
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
- 1.2.2 T Cell Engagers
- 1.2.3 NK Cell Engagers
- 1.3 Market by Application
- 1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2017 VS 2021 VS 2028
- 1.3.2 Hematological Cancers
- 1.3.3 Solid Tumors
- 1.4 Study Objectives
- 1.5 Years Considered
- 2 GLOBAL GROWTH TRENDS
- 2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Perspective (2017-2028)
- 2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Trends by Regions
- 2.2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions: 2017 VS 2021 VS 2028
- 2.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Regions (2017-2022)
- 2.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028)
- 2.2.4 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028
- 2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Dynamic
- 2.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
- 2.3.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
- 2.3.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
- 2.3.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
- 3 COMPETITION LANDSCAPE BY KEY PLAYERS
- 3.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue
- 3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue (2017-2022)
- 3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Players (2017-2022)
- 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue
- 3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio
- 3.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 2 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021
- 3.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Players Head office and Area Served
- 3.6 Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
- 3.7 Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
- 3.8 Mergers & Acquisitions, Expansion Plans
- 4 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY TYPE
- 4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Type (2017-2022)
- 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028)
- 5 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY APPLICATION
- 5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Application (2017-2022)
- 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028)
- 6 NORTH AMERICA
- 6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
- 6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
- 6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
- 6.4 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
- 6.4.1 United States
- 6.4.2 Canada
- 6.4.3 Mexico
- 7 EUROPE
- 7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
- 7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
- 7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
- 7.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 8 ASIA-PACIFIC
- 8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
- 8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
- 8.3 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
- 8.4 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 Southeast Asia
- 8.4.5 India
- 9 SOUTH AMERICA
- 9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
- 9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
- 9.3 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
- 9.4 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
- 9.4.1 Brazil
- 10 MIDDLE EAST & AFRICA
- 10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
- 10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
- 10.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
- 10.4 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
- 10.4.1 Middle East
- 10.4.2 Africa
- 11 KEY PLAYERS PROFILES
- 11.1 Amgen
- 11.1.1 Amgen Company Details
- 11.1.2 Amgen Business Overview
- 11.1.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.1.4 Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
- 11.1.5 Amgen Recent Development
- 11.2 Immunocore
- 11.2.1 Immunocore Company Details
- 11.2.2 Immunocore Business Overview
- 11.2.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.2.4 Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
- 11.2.5 Immunocore Recent Development
- 11.3 Johnson & Johnson
- 11.3.1 Johnson & Johnson Company Details
- 11.3.2 Johnson & Johnson Business Overview
- 11.3.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.3.4 Johnson & Johnson Recent Development
- 11.4 Roche
- 11.4.1 Roche Company Details
- 11.4.2 Roche Business Overview
- 11.4.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.4.4 Roche Recent Development
- 11.5 Pfizer
- 11.5.1 Pfizer Company Details
- 11.5.2 Pfizer Business Overview
- 11.5.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.5.4 Pfizer Recent Development
- 11.6 AbbVie
- 11.6.1 AbbVie Company Details
- 11.6.2 AbbVie Business Overview
- 11.6.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.6.4 AbbVie Recent Development
- 11.7 MacroGenics
- 11.7.1 MacroGenics Company Details
- 11.7.2 MacroGenics Business Overview
- 11.7.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.7.4 MacroGenics Recent Development
- 11.8 Regeneron
- 11.8.1 Regeneron Company Details
- 11.8.2 Regeneron Business Overview
- 11.8.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
- 11.8.4 Regeneron Recent Development
- 11.9 Astellas Pharma
- 11.9.1 Astellas Pharma Company Details
- 11.9.2 Astellas Pharma Business Overview
- 11.9.3 Astellas Pharma Recent Development
- 11.10 GEMoaB Monoclonals
- 11.10.1 GEMoaB Monoclonals Company Details
- 11.10.2 GEMoaB Monoclonals Business Overview
- 11.10.3 GEMoaB Monoclonals Recent Development
- 11.11 Molecular Partners
- 11.11.1 Molecular Partners Company Details
- 11.11.2 Molecular Partners Business Overview
- 11.11.3 Molecular Partners Recent Development
- 11.12 AstraZeneca
- 11.12.1 AstraZeneca Company Details
- 11.12.2 AstraZeneca Business Overview
- 11.12.3 AstraZeneca Recent Development
- 11.13 Merck
- 11.13.1 Merck Company Details
- 11.13.2 Merck Business Overview
- 11.13.3 Merck Recent Development
- 11.14 Eli Lilly
- 11.14.1 Eli Lilly Company Details
- 11.14.2 Eli Lilly Business Overview
- 11.14.3 Eli Lilly Recent Development
- 11.15 IGM Biosciences
- 11.15.1 IGM Biosciences Company Details
- 11.15.2 IGM Biosciences Business Overview
- 11.15.3 IGM Biosciences Recent Development
- 11.16 Novartis
- 11.16.1 Novartis Company Details
- 11.16.2 Novartis Business Overview
- 11.16.3 Novartis Recent Development
- 11.17 CytomX Therapeutics
- 11.17.1 CytomX Therapeutics Company Details
- 11.17.2 CytomX Therapeutics Business Overview
- 11.17.3 CytomX Therapeutics Recent Development
- 11.18 Lava Therapeutics
- 11.18.1 Lava Therapeutics Company Details
- 11.18.2 Lava Therapeutics Business Overview
- 11.18.3 Lava Therapeutics Recent Development
- 11.19 Takeda
- 11.19.1 Takeda Company Details
- 11.19.2 Takeda Business Overview
- 11.19.3 Takeda Recent Development
- 12 ANALYST'S VIEWPOINTS/CONCLUSIONS
- 13 APPENDIX
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details
- List of Tables
- Table 1. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
- Table 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
- Table 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (US$ Million): 2017 VS 2021 VS 2028
- Table 4. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (2017-2022) & (US$ Million)
- Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2017-2022)
- Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028) & (US$ Million)
- Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2023-2028)
- Table 8. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
- Table 9. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
- Table 10. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
- Table 11. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
- Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Players (2017-2022) & (US$ Million)
- Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Players (2017-2022)
- Table 14. Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies as of 2022)
- Table 15. Ranking of Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Companies by Revenue (US$ Million) in 2021
- Table 16. Global 5 Largest Players Market Share by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (CR5 and HHI) & (2017-2022)
- Table 17. Key Players Headquarters and Area Served
- Table 18. Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
- Table 19. Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
- Table 20. Mergers & Acquisitions, Expansion Plans
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook